ATE482193T1 - Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen - Google Patents

Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen

Info

Publication number
ATE482193T1
ATE482193T1 AT04720863T AT04720863T ATE482193T1 AT E482193 T1 ATE482193 T1 AT E482193T1 AT 04720863 T AT04720863 T AT 04720863T AT 04720863 T AT04720863 T AT 04720863T AT E482193 T1 ATE482193 T1 AT E482193T1
Authority
AT
Austria
Prior art keywords
indoloneacetamide
derivatives
production
indoloneacetamide derivatives
Prior art date
Application number
AT04720863T
Other languages
English (en)
Inventor
Jean-Philippe Starck
Benoit Kenda
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE482193T1 publication Critical patent/ATE482193T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04720863T 2003-03-31 2004-03-16 Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen ATE482193T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03007214 2003-03-31
PCT/EP2004/002691 WO2004087658A1 (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses

Publications (1)

Publication Number Publication Date
ATE482193T1 true ATE482193T1 (de) 2010-10-15

Family

ID=33104041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720863T ATE482193T1 (de) 2003-03-31 2004-03-16 Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen

Country Status (18)

Country Link
US (2) US7645887B2 (de)
EP (1) EP1620399B1 (de)
JP (1) JP2006522041A (de)
KR (1) KR20050119186A (de)
CN (1) CN100364973C (de)
AR (1) AR043959A1 (de)
AT (1) ATE482193T1 (de)
AU (1) AU2004226288A1 (de)
BR (1) BRPI0408863A (de)
CA (1) CA2520568A1 (de)
DE (1) DE602004029245D1 (de)
ES (1) ES2353461T3 (de)
MX (1) MXPA05009089A (de)
NO (1) NO20055026L (de)
RU (1) RU2005131317A (de)
TW (1) TW200508197A (de)
WO (1) WO2004087658A1 (de)
ZA (1) ZA200507231B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US20070191447A1 (en) * 2004-02-23 2007-08-16 Toru Kodo Novel heterocyclic compound
WO2006008067A1 (en) * 2004-07-22 2006-01-26 Ucb, S.A. Indolone derivatives, processes for preparing them and their uses
CA2604617C (en) 2005-04-28 2014-06-17 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
EP2308867A3 (de) * 2005-06-01 2011-10-19 UCB Pharma S.A. 2-Oxo-1-pyrrolidin-Derivate, Verfahren zu deren Herstellung und deren Verwendungen
US7790726B2 (en) * 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
AR059265A1 (es) 2006-02-07 2008-03-19 Astrazeneca Ab Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1)
DK2010493T3 (en) * 2006-04-12 2016-05-02 Merck Sharp & Dohme PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS
WO2008133933A1 (en) * 2007-04-26 2008-11-06 Trustees Of Columbia University In The City Of New York Methods, systems, and compositions for treating or ameliorating the effects of a non-congenital hypertonia
WO2008132139A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
US20100249176A1 (en) * 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
CA2701594C (en) * 2007-10-24 2014-02-18 Merck Sharp & Dohme Corp. Heterocycle phenyl amide t-type calcium channel antagonists
CA2740610C (en) 2008-10-16 2020-01-07 The Johns Hopkins University Synaptic vesicle protein 2a inhibitors for treating age-related cognitive impairment
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
HK1215170A1 (zh) 2012-11-14 2016-08-19 The Johns Hopkins University 治療精神分裂症的方法和組合物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
PH12021552653A1 (en) 2014-01-21 2023-07-17 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
CN107540597A (zh) * 2017-09-22 2018-01-05 苏州大学 N‑乙酰二甲胺基吲哚‑2‑酮衍生物的制备方法
US20210214359A1 (en) * 2018-05-29 2021-07-15 New York University Compounds and Methods for Treating Bacterial Infections
KR102669101B1 (ko) * 2021-08-10 2024-05-27 충북대학교 산학협력단 신규한 옥소인돌린 기반 아세토히드라지드 및 이를 유효성분으로 포함하는 항암제 조성물
CN114874127B (zh) * 2022-05-23 2023-06-09 中国药科大学 一种二氟羰基化吲哚酮类化合物的制备方法
IL319072A (en) 2022-08-19 2025-04-01 Agenebio Inc History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0022317B1 (de) 1979-06-12 1983-09-21 Fujisawa Pharmaceutical Co., Ltd. 2-Oxo-benzothiazolin-, Benzoxazolin- oder Indolin-Derivate, deren Herstellung und derartige Verbindungen enthaltende pharmazeutische Zusammensetzungen
JPS5697268A (en) * 1979-12-28 1981-08-05 Fujisawa Pharmaceut Co Ltd Lower alkanoic acid derivative, salt and preparation thereof and preventing agent and remedy for diabetic complication containing the same as active constituent
SU841264A1 (ru) 1980-02-20 1995-11-10 Научно-исследовательский институт фармакологии АМН СССР Амид-2-оксо-1-индолинуксусной кислоты, обладающий противосудорожной активностью
DE3413572A1 (de) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Oxindol-verbindungen zur behandlung der epilepsie
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
DK288287A (da) * 1986-06-09 1987-12-10 Pfizer Heterocycliske forbindelser samt farmaceutiske praeparater til behandling af allergiske eller inflammatoriske tilstande
JPH0195766A (ja) 1987-10-08 1989-04-13 Tamanoisu Kk 無蒸煮アルコール醪からの食酢の製造法
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
CA2036307C (en) 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
BR9200951A (pt) * 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5514690A (en) 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
SE9302080D0 (sv) * 1993-06-16 1993-06-16 Ab Astra New compounds
JPH07304736A (ja) * 1994-05-10 1995-11-21 Kyowa Hakko Kogyo Co Ltd インドール誘導体
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
FR2738818B1 (fr) * 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
NZ333696A (en) * 1996-07-08 2000-06-23 Du Pont Pharm Co Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of trypsin like protease enzymes like thrombin and Xa factor
JPH1095766A (ja) * 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
WO2002030868A1 (en) * 2000-10-13 2002-04-18 Bristol-Myers Squibb Company Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
WO2004082605A2 (en) * 2003-03-14 2004-09-30 Merck & Co. Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
WO2006008067A1 (en) * 2004-07-22 2006-01-26 Ucb, S.A. Indolone derivatives, processes for preparing them and their uses

Also Published As

Publication number Publication date
EP1620399A1 (de) 2006-02-01
AR043959A1 (es) 2005-08-17
JP2006522041A (ja) 2006-09-28
KR20050119186A (ko) 2005-12-20
ES2353461T3 (es) 2011-03-02
RU2005131317A (ru) 2006-02-27
AU2004226288A1 (en) 2004-10-14
US20070043038A1 (en) 2007-02-22
WO2004087658A1 (en) 2004-10-14
CN1768036A (zh) 2006-05-03
ZA200507231B (en) 2006-11-29
US7964593B2 (en) 2011-06-21
NO20055026D0 (no) 2005-10-28
MXPA05009089A (es) 2005-11-17
NO20055026L (no) 2005-12-22
CN100364973C (zh) 2008-01-30
US7645887B2 (en) 2010-01-12
EP1620399B1 (de) 2010-09-22
DE602004029245D1 (de) 2010-11-04
CA2520568A1 (en) 2004-10-14
HK1089768A1 (zh) 2006-12-08
US20100069375A1 (en) 2010-03-18
TW200508197A (en) 2005-03-01
BRPI0408863A (pt) 2006-04-11

Similar Documents

Publication Publication Date Title
ATE556077T1 (de) Tetrahydrochinolinderivate und verfahren zu deren herstellung
ATE482193T1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
ATE476412T1 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
EP1743174A4 (de) Multimodale nanostrukturen, verfahren zu deren herstellung und verwendung
DE502005010912D1 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE60208373D1 (de) Polyaryleneether-polyolefinzusammensetzung, verfahren zu deren herstellung und formassen daraus
DE60333438D1 (de) Beschichtete gefässprothesen, verfahren zu deren herstellung und verwendung derselben
DE602006012666D1 (de) Ren eignen und verfahren zu deren herstellung
ATE346065T1 (de) Substituierte thiazol- benzoisothiazoldioxidderivative, verfahren zu deren herstellung und deren verwendung
DE602004030331D1 (de) Dreiteilige wegwerfunterwäsche mit gefaltetem schritt und verfahren zu dessen herstellung
DE50310782D1 (de) Piezoaktor und verfahren zu dessen herstellung
ATE348609T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
DE602004008991D1 (de) Umlenkbeschlag und verfahren zu dessen herstellung
ATE465990T1 (de) Arylalkylcarbamatderivate, verfahren zur ihrer herstellung und deren therapeutischen anwendungen
ATE433453T1 (de) Kondensierte pyrrolocarbazole und verfahren zu deren herstellung
ATE496046T1 (de) Arylvinylazacycloalkan-verbindungen und verfahren zu deren herstellung und verwendung
DE502004005578D1 (de) Hochtackige klebmasse, verfahren zu deren herstellung und deren verwendung
DE50311585D1 (de) Fahrzeugtür und verfahren zu deren herstellung
DE602004028584D1 (de) Emulsionsförmiger haftklebstoff und verfahren zu seiner herstellung
DE502004010268D1 (de) Bitleitungsstruktur sowie verfahren zu deren herstellung
ATA3752003A (de) Verbundwerkstoff und verfahren zu dessen herstellung
ATE404532T1 (de) Acyl-3-carboxyphenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
DE60311494D1 (de) Aktoreinheit und Verfahren zu deren Herstellung
DE502004006798D1 (de) Bauelement und verfahren zu dessen herstellung
DE602004026157D1 (de) Proteinkomplex, verfahren zu dessen herstellung und verwendung davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties